Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia.

Hypertension (Dallas, Tex. : 1979)

Waller JP, Howell JA, Peterson H, George EM, Bidwell GL.
PMID: 34719237
Hypertension. 2021 Dec;78(6):1888-1901. doi: 10.1161/HYPERTENSIONAHA.121.17713. Epub 2021 Nov 01.

[Figure: see text].

Cite
Waller JP, Howell JA, Peterson H, et al. Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension. 2021;78(6):1888-1901doi: 10.1161/HYPERTENSIONAHA.121.17713.
Waller, J. P., Howell, J. A., Peterson, H., George, E. M., & Bidwell, G. L. (2021). Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension (Dallas, Tex. : 1979), 78(6), 1888-1901. https://doi.org/10.1161/HYPERTENSIONAHA.121.17713
Waller, Jamarius P, et al. "Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia." Hypertension (Dallas, Tex. : 1979) vol. 78,6 (2021): 1888-1901. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.17713
Waller JP, Howell JA, Peterson H, George EM, Bidwell GL. Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension. 2021 Dec;78(6):1888-1901. doi: 10.1161/HYPERTENSIONAHA.121.17713. Epub 2021 Nov 01. PMID: 34719237; PMCID: PMC8585700.
Copy Download .nbib Format: NLM
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.

Vascular cell

George EM, Liu H, Robinson GG, Mahdi F, Perkins E, Bidwell GL.
PMID: 25653833
Vasc Cell. 2015 Jan 24;7(1):1. doi: 10.1186/s13221-014-0026-3. eCollection 2015.

BACKGROUND: Therapeutic angiogenesis with vascular endothelial growth factor (VEGF), delivered either via recombinant protein infusion or via gene therapy, has shown promise in preclinical models of various diseases including myocardial infarction, renovascular disease, preeclampsia, and neurodegenerative disorders. However, dosing,...

Cite
George EM, Liu H, Robinson GG, et al. Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell. 2015;7(1):1doi: 10.1186/s13221-014-0026-3.
George, E. M., Liu, H., Robinson, G. G., Mahdi, F., Perkins, E., & Bidwell, G. L. (2015). Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vascular cell, 7(1), 1. https://doi.org/10.1186/s13221-014-0026-3
George, Eric M, et al. "Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis." Vascular cell vol. 7,1 (2015): 1. doi: https://doi.org/10.1186/s13221-014-0026-3
George EM, Liu H, Robinson GG, Mahdi F, Perkins E, Bidwell GL. Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell. 2015 Jan 24;7(1):1. doi: 10.1186/s13221-014-0026-3. eCollection 2015. PMID: 25653833; PMCID: PMC4316602.
Copy Download .nbib Format: NLM
Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer.

Pharmaceutics

Mahdi F, Chade AR, Bidwell GL.
PMID: 31635263
Pharmaceutics. 2019 Oct 18;11(10). doi: 10.3390/pharmaceutics11100542.

Elastin-like polypeptides (ELP) are versatile protein biopolymers used in drug delivery due to their modular nature, allowing fusion of therapeutics and targeting agents. We previously developed an ELP fusion with vascular endothelial growth factor (VEGF) and demonstrated its therapeutic...

Cite
Mahdi F, Chade AR, Bidwell GL. Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics. 2019;11(10)doi: 10.3390/pharmaceutics11100542.
Mahdi, F., Chade, A. R., & Bidwell, G. L. (2019). Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics, 11(10), . https://doi.org/10.3390/pharmaceutics11100542
Mahdi, Fakhri, et al. "Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer." Pharmaceutics vol. 11,10 (2019). doi: https://doi.org/10.3390/pharmaceutics11100542
Mahdi F, Chade AR, Bidwell GL. Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics. 2019 Oct 18;11(10). doi: 10.3390/pharmaceutics11100542. PMID: 31635263; PMCID: PMC6835230.
Copy Download .nbib Format: NLM
Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Physiology (Bethesda, Md.)

Bidwell GL.
PMID: 34486397
Physiology (Bethesda). 2021 Nov 01;36(6):367-381. doi: 10.1152/physiol.00026.2021. Epub 2021 Sep 06.

Elastin-like polypeptides (ELPs) are bioengineered proteins that have a unique physical property, a thermally triggered inverse phase transition, that can be exploited for drug delivery. ELP-fusion proteins can be used as soluble biologics, thermally targeted drug carriers, self-assembling nanoparticles,...

Cite
Bidwell GL. Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda). 2021;36(6):367-381doi: 10.1152/physiol.00026.2021.
Bidwell, G. L. (2021). Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda, Md.), 36(6), 367-381. https://doi.org/10.1152/physiol.00026.2021
Bidwell, Gene L. "Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform." Physiology (Bethesda, Md.) vol. 36,6 (2021): 367-381. doi: https://doi.org/10.1152/physiol.00026.2021
Bidwell GL. Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda). 2021 Nov 01;36(6):367-381. doi: 10.1152/physiol.00026.2021. Epub 2021 Sep 06. PMID: 34486397; PMCID: PMC8560375.
Copy Download .nbib Format: NLM
Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia.

Hypertension (Dallas, Tex. : 1979)

Waller JP, Howell JA, Peterson H, George EM, Bidwell GL.
PMID: 34719237
Hypertension. 2021 Dec;78(6):1888-1901. doi: 10.1161/HYPERTENSIONAHA.121.17713. Epub 2021 Nov 01.

[Figure: see text].

Cite
Waller JP, Howell JA, Peterson H, et al. Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension. 2021;78(6):1888-1901doi: 10.1161/HYPERTENSIONAHA.121.17713.
Waller, J. P., Howell, J. A., Peterson, H., George, E. M., & Bidwell, G. L. (2021). Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension (Dallas, Tex. : 1979), 78(6), 1888-1901. https://doi.org/10.1161/HYPERTENSIONAHA.121.17713
Waller, Jamarius P, et al. "Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia." Hypertension (Dallas, Tex. : 1979) vol. 78,6 (2021): 1888-1901. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.17713
Waller JP, Howell JA, Peterson H, George EM, Bidwell GL. Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia. Hypertension. 2021 Dec;78(6):1888-1901. doi: 10.1161/HYPERTENSIONAHA.121.17713. Epub 2021 Nov 01. PMID: 34719237; PMCID: PMC8585700.
Copy Download .nbib Format: NLM
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia.

Frontiers in pharmacology

Bidwell GL, George EM.
PMID: 25249978
Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014.

The last several decades have seen intensive research into the molecular mechanisms underlying the symptoms of preeclampsia. While the underlying cause of preeclampsia is believed to be defective placental development and resulting placental ischemia, it is only recently that...

Cite
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014;5:201doi: 10.3389/fphar.2014.00201.
Bidwell, G. L., & George, E. M. (2014). Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Frontiers in pharmacology, 5201. https://doi.org/10.3389/fphar.2014.00201
Bidwell, Gene L, and George, Eric M. "Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia." Frontiers in pharmacology vol. 5 (2014): 201. doi: https://doi.org/10.3389/fphar.2014.00201
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014. PMID: 25249978; PMCID: PMC4155872.
Copy Download .nbib Format: NLM
Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system.

Drug design, development and therapy

McGowan JW, Shao Q, Vig PJ, Bidwell GL.
PMID: 27660412
Drug Des Devel Ther. 2016 Sep 06;10:2803-2813. doi: 10.2147/DDDT.S106216. eCollection 2016.

Bypassing the blood-brain barrier is one of the primary considerations when designing compounds intended to function in the central nervous system (CNS). Intranasal (IN) administration of otherwise blood-brain barrier impermeable molecules can result in high CNS concentrations and low...

Cite
McGowan JW, Shao Q, Vig PJ, et al. Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system. Drug Des Devel Ther. 2016;10:2803-2813doi: 10.2147/DDDT.S106216.
McGowan, J. W., Shao, Q., Vig, P. J., & Bidwell, G. L. (2016). Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system. Drug design, development and therapy, 102803-2813. https://doi.org/10.2147/DDDT.S106216
McGowan, Jeremy Wd, et al. "Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system." Drug design, development and therapy vol. 10 (2016): 2803-2813. doi: https://doi.org/10.2147/DDDT.S106216
McGowan JW, Shao Q, Vig PJ, Bidwell GL. Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system. Drug Des Devel Ther. 2016 Sep 06;10:2803-2813. doi: 10.2147/DDDT.S106216. eCollection 2016. PMID: 27660412; PMCID: PMC5019317.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries